逍遥散联合介入术对肝郁脾虚型肝癌患者临床疗效观察

目的:观察肝郁脾虚型肝癌介入术后联合逍遥散的临床疗效。方法:选择符合纳入标准和肝郁脾虚辨证标准的56例原发性肝癌患者,随机分为治疗组和对照组各28例。对照组单纯介入疗法,采用5-FU、MMC和DDP经股动脉灌注化疗,碘化油栓塞,4周左右重复1次,3次为1个疗程。治疗组在对照组基础上加服逍遥散加减汤剂,日1剂,连续服1个月。结果:两组患者近期疗效比较差异无统计学意义(P<0.05),总有效率治疗组并未见高于对照组;但两组生存质量(卡氏评分)改善情况治疗组高于对照组(P<0.05),常见症状乏力、恶心呕吐、腹胀、肝区胀痛等缓解情况,治疗组明显优于对照组(P<0.05)。结论:肝郁脾虚型肝癌介入术后联合逍遥散的临床疗效显著,能够缓解常见不良症状,减轻不良反应,提高患者的生活质量。

Clinical Observation on Xiaoyao Powder Combined with Intervention of Hepatocellular Carcinoma of Liver-depression and Spleen-deficiency Syndrome

Objective:To observe the effect of Xiaoyao Powder combined with intervention on liver cancer of liver-depression and spleen-deficiency syndrome.Method:56 patients with primary liver cancer who were met the inclusion criteria,were randomly divided into treatment group and control group,28 cases in each group.The control group was treated with intervention therapy,using 5-FU,MMC and DDP through the femoral artery infusion chemotherapy,Iodized oil embolization,which was repeated every 4 weeks and 3 times for a course.Treatment group was given Xiaoyao Powder besides the same therapy as the control group,1 dose a day,which lasted for 1 month.Result:Recent efficacy of two groups had no statistically significant difference(P<0.05),the total effective in treatment group was not superior to that in control group;however,quality of life(Karnofsky score) improvement in treatment group was higher(P<0.05),the conditions of fatigue,nausea,vomiting,abdominal distension and liver pain in the treatment group were better improved than those in the control group(P<0.05).Conclusion:Xiaoyao Powder combined with intervention of hepatocellular carcinoma of liver-depression and spleen-deficiency syndrome has obvious clinical effect,which can alleviate common adverse symptoms,reduce side effects and improve patient quality of life.